A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Key Inclusion Criteria: Subjects may be enrolled in this study only if they satisfy all the following criteria (NOTE: This is not an exhaustive list): * Subjects aged ≥18 years. * ECOG performance status ≤ 2 * Subjects with advanced relapsed, refractory, or resistant hematological malignancies, as defined below: Part 1: * Subjects with documented IDH mutation per local or institutional next generation sequence (NGS). * Subjects must be refractory to or intolerant of established therapies. * Subjects who have received prior IDH inhibitor treatment may be enrolled in the escalation phase. Part 2: * Subjects with documented IDH mutation of any of these subsets: IDH1 (R132C), IDH1 (R132H), IDH (R140Q), and IDH2 (R172K), including co-mutations and any combination thereof per local and institutional NGS. * Patients must have received at least 1 prior line of therapy with an IDH inhibitor. An established standard of care with proven benefit for which the patient is eligible, must not be available at the time of enrollment. * Patients with AML must not have standard therapeutic options available (including IDH inhibitors where approved) and have the following: * i. Relapsed AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents; * ii. Primary refractory AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents. * iii. Relapsed/refractory AML that has progressed on prior IDH treatment Key Exclusion Criteria: S…